Recent Updates — IMRN
Immuron Limited reported unaudited first-quarter fiscal 2027 global sales of AUD$2.2 million, representing a 9% increase compared to the prior comparative period and a 5% rise from the previous quarter. Australian sales contributed AUD$1.8 million, up 14% year-over-year, driven by a successful brand re-launch of Travelan® that outpaced category growth. Canadian sales surged 286% to AUD$0.1 million following increased awareness and sampling at major conferences. Conversely, U.S. sales declined 19% to AUD$0.3 million due to high prior-year purchases during Amazon Prime Day and temporary logistics delays, though inventory has since been replenished. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.
Immuron Limited has amended its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to decrease the aggregate maximum offering price of American Depositary Shares available for sale from approximately $4.85 million to $2,006,769. This adjustment was made pursuant to General Instruction I.B.5 of Form F-3, which excludes securities previously sold during the 12-calendar month period ending October 23, 2026. The company filed a Current Prospectus Supplement to reflect this reduction in available capital under its existing shelf registration statement. Immuron Limited is an Australian biotechnology company focused on developing immunotherapies for cancer.
Immuron Limited is seeking shareholder approval at its Annual General Meeting on November 18, 2026, to renew its 10% placement capacity under ASX Listing Rule 7.1A and extend its Omnibus Incentive Plan for a further three years. The company also proposes the re-election of director Dr Jeannette Joughin and the election of non-board endorsed candidate Mr Param Lally. These resolutions are standard governance items, with no material financial impact or strategic transaction announced in this filing.
Immuron Limited announced the publication of data from its Phase 2 clinical trial for once-daily oral Travelan in Scientific Reports. The study demonstrated a statistically significant 50% reduction in enterotoxigenic Escherichia coli (ETEC) challenge-related adverse events versus placebo, alongside reductions in moderate-to-severe and severe diarrhea. Although the trial missed its primary efficacy endpoints due to a lower-than-anticipated placebo attack rate reducing statistical power, results trended favorably across multiple clinically meaningful endpoints. The company plans to investigate a next-generation delayed-release capsule formulation with a higher payload in larger studies. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.